Kiker Wealth Management LLC acquired a new stake in Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 15,802 shares of the medical instruments supplier's stock, valued at approximately $1,234,000. Haemonetics comprises approximately 1.0% of Kiker Wealth Management LLC's investment portfolio, making the stock its 24th biggest holding.
A number of other institutional investors and hedge funds also recently bought and sold shares of HAE. Segall Bryant & Hamill LLC raised its stake in shares of Haemonetics by 0.7% in the third quarter. Segall Bryant & Hamill LLC now owns 62,621 shares of the medical instruments supplier's stock worth $5,033,000 after acquiring an additional 407 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Haemonetics by 439.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 220,453 shares of the medical instruments supplier's stock worth $17,720,000 after purchasing an additional 179,621 shares during the last quarter. Intech Investment Management LLC lifted its holdings in Haemonetics by 62.9% during the 3rd quarter. Intech Investment Management LLC now owns 22,329 shares of the medical instruments supplier's stock worth $1,795,000 after buying an additional 8,626 shares in the last quarter. Cerity Partners LLC boosted its position in Haemonetics by 31.1% in the 3rd quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier's stock valued at $712,000 after buying an additional 2,102 shares during the last quarter. Finally, Westfield Capital Management Co. LP increased its stake in shares of Haemonetics by 10.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier's stock valued at $66,206,000 after buying an additional 80,783 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Trading Down 1.6 %
Shares of HAE stock traded down $1.06 on Tuesday, hitting $63.39. The stock had a trading volume of 529,137 shares, compared to its average volume of 649,929. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97. The company has a fifty day moving average price of $66.99 and a two-hundred day moving average price of $74.96. The firm has a market cap of $3.18 billion, a P/E ratio of 24.96, a PEG ratio of 1.11 and a beta of 0.43.
Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research note on Friday, December 6th. They issued an "overweight" rating and a $116.00 target price on the stock. Raymond James reissued a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. JMP Securities reduced their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. Finally, Needham & Company LLC dropped their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $101.22.
Check Out Our Latest Report on HAE
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
